Overview

• The MHRA recalled the inhalers after CD Pharma Ltd flagged that four production batches’ outer cartons misstated the delivered dose per actuation.
• The labelling error underrepresents each puff as delivering roughly half the intended fluticasone and formoterol amounts, despite the inhalers containing the correct 250 micrograms/10 micrograms dosage.
• Pharmacies must cease dispensing the affected batches and return quarantined stock to suppliers through approved channels without issuing the inhalers to patients.
• Officials have confirmed the packaging fault does not affect the medicine’s quality or its efficacy in controlling asthma symptoms.
• Patients are advised to continue using their prescribed inhaler and to report any suspected adverse reactions via the MHRA Yellow Card Scheme.